Skip to main content

Table 2 Characteristics for the cohort stratified by the NPS improvement status

From: Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis

Patients

 

ntNPSi

tNPSi

 

n = 65

n = 33

n = 32

Male/female

 n

42/23

20/13

22/10

 %

64.6/35.4

60.6/39.4

68.8/31.3

Age, mean years (SD)

51.3 (12.7)

50.3 (13.5)

52.4 (11.7)

Asthma n/%

41/63.1

17/51.5

24/75.0

AERD n/%

32/49.2

13/39.4

19/59.4

Prior ESS, mean number (SD)

2.0 (1.5)

1.9 (1.5)

2.2 (1.5)

Pretreatment NPS

 Median

4

2

4

 Min.–max

1–8

1–6

1–8

  1. NPS nasal polyp score, ntNPSi no total NPS improvement, tNPSi total NPS improvement, n number of patients, % percentage of patients, AERD aspirin-exacerbated respiratory disease, ESS endoscopic sinus surgery, SD standard deviation, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, min. minimum value, max. maximum value
Back to article page

Journal of Otolaryngology - Head & Neck Surgery

ISSN: 1916-0216

Contact us